Integral Health Asset Management LLC Acquires Shares of 40,000 Amgen Inc. (NASDAQ:AMGN)

Integral Health Asset Management LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,000 shares of the medical research company’s stock, valued at approximately $12,498,000. Amgen makes up about 1.2% of Integral Health Asset Management LLC’s portfolio, making the stock its 27th largest position.

Other large investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter valued at $26,000. Horizon Financial Services LLC acquired a new stake in shares of Amgen during the first quarter worth about $28,000. United Community Bank acquired a new stake in shares of Amgen during the fourth quarter worth about $29,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the second quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the second quarter worth about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on AMGN shares. Oppenheimer reiterated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. Royal Bank of Canada increased their price target on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. TD Cowen increased their price target on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Argus increased their price target on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Eleven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $327.28.

Amgen Stock Up 0.4 %

AMGN stock opened at $337.38 on Monday. The company’s 50 day simple moving average is $329.57 and its 200-day simple moving average is $306.03. The firm has a market capitalization of $180.98 billion, a PE ratio of 48.20, a P/E/G ratio of 2.93 and a beta of 0.61. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.00 earnings per share. Equities analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.67%. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.